Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study
Jazyk angličtina Země Nizozemsko Médium print-electronic
Typ dokumentu srovnávací studie, časopisecké články, multicentrická studie, pozorovací studie, práce podpořená grantem
PubMed
30447419
DOI
10.1016/j.jneuroim.2018.11.002
PII: S0165-5728(18)30332-1
Knihovny.cz E-zdroje
- Klíčová slova
- Anti-drug antibodies, Bridging ELISA, Interferon-beta, Luciferase-based bioassay, Multiple sclerosis, Neutralizing antibodies,
- MeSH
- biotest MeSH
- ELISA MeSH
- imunologické faktory imunologie terapeutické užití MeSH
- interferon beta imunologie terapeutické užití MeSH
- lidé MeSH
- neutralizační testy metody MeSH
- neutralizující protilátky krev MeSH
- roztroušená skleróza krev farmakoterapie MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- pozorovací studie MeSH
- práce podpořená grantem MeSH
- srovnávací studie MeSH
- Názvy látek
- imunologické faktory MeSH
- interferon beta MeSH
- neutralizující protilátky MeSH
Two validated assays, a bridging ELISA and a luciferase-based bioassay, were compared for detection of anti-drug antibodies (ADA) against interferon-beta (IFN-β) in patients with multiple sclerosis. Serum samples were tested from patients enrolled in a prospective study of 18 months. In contrast to the ELISA, when IFN-β-specific rabbit polyclonal and human monoclonal antibodies were tested, the bioassay was the more sensitive to detect IFN-β ADA in patients' sera. For clinical samples, selection of method of ELISA should be evaluated prior to the use of a multi-tiered approach. A titer threshold value is reported that may be used as a predictor for persistently positive neutralizing ADA.
Clinic for Neurology 2 Kepler University Clinic Med Campus 3 Linz Austria
Department of Clinical Neuroscience Karolinska Institutet Stockholm Sweden
Department of Neurology Medical University of Graz Graz Austria
Department of Neurology Technische Universität München Munich Germany
GlaxoSmithKline R and D Uxbridge Middlesex United Kingdom
Hospital Universitari Vall d'Hebron Centre d'Esclerosi Múltiple de Catalunya Barcelona Spain
Innsbruck Medical University Innsbruck Austria
INSERM UMR 996 Univ Paris Sud Faculty of Pharmacy Université Paris Saclay Châtenay Malabry France
Ipsen Biopharm Ltd Berkshire United Kingdom
Merck NBE Bioanalytics Ivrea Colleretto Giacosa Italy
Sanofi Aventis Germany Frankfurt Am Main Germany
University of Düsseldorf Medical Faculty Department of Neurology Düsseldorf Germany
Citace poskytuje Crossref.org